Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Operating Expenses (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Operating Expenses data on record, last reported at $1.9 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 42.28% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $6.5 million, up 6.03%, while the annual FY2024 figure was $5.6 million, 56.54% down from the prior year.
  • Operating Expenses reached $1.9 million in Q3 2025 per CYCN's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $19.2 million in Q2 2021 and bottomed at -$13.1 million in Q3 2022.
  • Average Operating Expenses over 5 years is $5.4 million, with a median of $1.9 million recorded in 2025.
  • Peak YoY movement for Operating Expenses: tumbled 212.2% in 2022, then soared 146.08% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $14.9 million in 2021, then tumbled by 70.04% to $4.5 million in 2022, then tumbled by 59.71% to $1.8 million in 2023, then fell by 27.35% to $1.3 million in 2024, then soared by 44.25% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $1.9 million in Q3 2025, $1.8 million in Q2 2025, and $1.5 million in Q1 2025.